Skip to content

Mindful Breathing and tDCS for Depression

Mindful Breathing and Neuromodulation for Depression in Young People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03897699
Enrollment
68
Registered
2019-04-01
Start date
2019-03-01
Completion date
2021-10-01
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depressive Disorder

Brief summary

This study will investigate whether transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC) can enhance the therapeutic effect of mindful breathing training (MBT) for adolescent depression. The objective is to enhance connectivity between the DLPFC with the amygdala and Default Mode Network (DMN) circuits as well as to enhance emotion regulation abilities and decrease rumination to reduce symptoms of depression. This will aid in the development of novel treatments for depression.

Detailed description

Aim 1: To demonstrate the feasibility of recruiting and randomizing adolescents with depression to a research protocol involving MBT and tDCS. The investigators expect that adolescents will be willing to enroll in a randomized trial involving MBT and tDCS. Aim 2: To test the tolerability of MBT and tDCS in adolescents. The investigators expect that MBT will be well-tolerated and that active tDCS will show no difference in tolerance compared to sham stimulation. Aim 3: To examine whether tDCS can enhance the effects of MBT. The investigators expect the MBT + tDCS group will show greater reduction in depressive symptoms compared to the MBT + sham stimulation group. Aim 4: To examine the mechanisms of MBT +/- tDCS treatment. The investigators expect that depression symptom improvement will be associated with decreased rumination, improvements in emotion regulation, increased task-based and resting state DLPFC-DMN and DLPFC-amygdala connectivity, as well as increased DLPFC activation and reduced amygdala activation during rumination and emotion processing tasks. The investigators also expect reduced alpha asymmetry and reduced LPP amplitude during emotion regulation and emotion processing. The investigators expect these changes will be greatest in the active tDCS + MBT group.

Interventions

DEVICETranscranial Direct Current Stimulation

A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\ 2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.

MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.

OTHERSham

Weak electrical current (\ 2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of major depressive disorder (MDD), Dysthymia, or Other specified/Unspecified Depressive Disorder based on MINI. * Experiencing current symptoms of depression as indexed by a MADRS-S score ≥ 13 * Ability to access the MBT online-based application (e.g., on a personal laptop, tablet, or cell phone) * Fluent in English

Exclusion criteria

* Any participant with a clinically defined neurological disorder or insult including, but not limited to, a condition likely to increase the risk of seizure; such as, space occupying brain lesion; any history of seizure; history of cerebrovascular accident; transient ischemic attack within two years; cerebral aneurysm; dementia; brain surgery; history or stroke or family history of epilepsy * Any participant with an increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure or history of significant head trauma with loss of consciousness for ≥ 5 minutes * Participants with conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the head excluding the mouth that cannot safely be removed. Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes * Participants with active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, and vagus nerve stimulators * Participants with pre-existing sores or lesions at the site of tDCS or EEG electrode placement * A hair style that would impede EEG and tDCS electrode contact (e.g., dread locks) * Any participant with a current or possibility of current pregnancy * Participants unable to give informed consent. * Participation in any investigational drug trial within 4 weeks of the baseline visit * Clinically significant laboratory abnormality or medical condition, that in the opinion of the investigator would hinder the participant in completing the procedures required by the study * Currently actively suicidal with intent and plan determined by the C-SSRS at the baseline visit. * A diagnosis of current or recent substance use disorder (within the past 12 months) * A diagnosis of Schizophrenia, Bipolar Disorder, or Autism * Unstable psychotherapy (therapy must be for at least 3 months prior to entry into the study, with no anticipation of change in the frequency or treatment focus of the therapeutic sessions over the duration of the study) * Recent change in dose of antidepressant medication (within 6 weeks prior to entry into the study). This includes all antidepressants and any adjunctive psychotropic medications that are being used to address problems related to mood or anxiety (e.g. antipsychotic medications, mood stabilizers) * Refusal to cooperate with study procedures

Design outcomes

Primary

MeasureTime frameDescription
Change in DLPFC Connectivity: AmygdalaBaseline and 5 weekChange in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: Right Amygdala and left DLPFC. Lower connectivity may represent a reduced tendency to engage in maladaptive, repetitive negative thinking. For r-values, 0 represents that the timeseries of the respective ROIs are not correlated. A better outcome may be indexed by lower connectivity (e.g., negative R values), which may represent a greater ability of the DLPFC to downregulate the amygdala and, which in turn may reduce the tendency to engage in maladaptive, repetitive negative thinking.
Change in DLPFC Connectivity: DMN5 weeks from baselineChange in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: default mode network and left DLPFC. Lower DLPFC and DMN connectivity may represent adaptive switching between thinking states to focus on a task at hand or to engage in more reflective, introspective thinking patterns. For r-values, 0 represents that the timeseries of the respective ROIs are not correlated. Change in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: default mode network and left DLPFC. A better outcome may be indexed by lower DLPFC and DMN connectivity (e.g., negative R values), which may represent adaptive switching between thinking states to focus on a task at hand or to engage in more reflective, introspective thinking patterns.

Secondary

MeasureTime frameDescription
Change in Rumination RRSBaseline and 9 weeksRuminative Response Scale (RRS) measures rumination, which refers to thoughts and behaviors centered around one's symptoms and their causes, as well as potential consequences. Nolen-Hoeksema, Morrow, & Fredrickson (1993) reported that ruminative thoughts correlated with depressed mood. They further reported a consistency in ruminative responses over a 30-day period. The RRS will be used to measure changes in rumination in the present study. The measure consists of a total of 22 statements that describe ruminative thoughts and participants are requested to rate each statement on a scale of 1 - 4, 1 being Almost Never and 4 being Almost Always. Change in rumination corresponds with a change in the total RRS score. Total scores range from 22 to 88.
Change in Mindfulness FMIBaseline and 9 weeksFreiburg Mindfulness Inventory (FMI) assesses curious attitude toward the mindfulness experience. The FMI contains 14 statements related to mindfulness experiences. Participants are requested to rate each statement according to a 4-point Likert scale ranging from Rarely to Almost Always. An increase in the FMI total score would indicate an increase in mindfulness. Walach et al. (2006) reported that the FMI is a valid and reliable measure of mindfulness. Total scores range from 14 to 56.
Change in Depression MADRS-SBaseline and 5 weeksMontgomery-Åsberg Depression Rating Scale - self-assessment (MADRS-S) measures change in severity of depression symptoms over time. Treatment response will be measured using the MADRS-S and a \ 50% reduction in depression severity, i.e. total MADRS-S score, will indicate a positive response to treatment. The scale includes 9 items that are rated by participants on a 4-point Likert scale ranging from 0 - 3. Half-point scores are also possible, i.e 0.5, 1.5, 2.5. Participants rate their symptoms from over the past 3 days and the range of total possible scores is 0 - 27, with a higher score indicating greater severity of symptoms. Bondolfi et al. (2010) found good internal consistency for the MADRS-S, as well as good concurrent validity between the MADRS (clinician administered) and the MADRS-S. Lastly, the MADRS-S was found to be sensitive to change in depression symptoms over time.
Tolerability: Enrollment and Drop-Out9 weeksNumber of participants enrolled. A high number of participants enrolled will indicate a higher level of tolerability of the treatment.
Tolerability: Drop-Out9 weeksNumber of participants who drop-out due to inability to tolerate treatment. A high number of participant drop-outs will indicate a lower level of tolerability of the treatment.
Safety: Serious and Non-Serious Adverse Events9 weeksMeasure of occurrence of negative side-effects from treatment. Side effects will be collected via participant self-report. Number of serious and non-serious adverse events will be considered in determining safety of the treatment. A higher number of adverse events will indicate lower treatment safety.
Change in Mindfulness MAASBaseline and 9 weeksMindful Attention and Awareness Scale (MAAS) measures presence or absence of awareness of what is happening in the present. The MAAS consists of 15 items. Participants are requested to rate each item according to a 6-point Likert scale with the following options: Almost Always, Very Frequently, Somewhat Frequently, Somewhat Infrequently, Very Infrequently, and Almost Never. Previous study reported that the MAAS was internally consistent and a reliable measure. MAAS score ranges from 1 to 6, with a higher score indicating a greater awareness of inner experiences and mindfulness. In the present study, an increase in the total MAAS score would indicate an increase in presence of awareness of what is happening in the present.

Countries

United States

Participant flow

Participants by arm

ArmCount
Active tDCS + Mindful Breathing Training
20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training Transcranial Direct Current Stimulation: A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\ 2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Mindful Breathing: MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
16
Sham tDCS + Mindful Breathing Training
The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session Mindful Breathing: MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web. Sham: Weak electrical current (\ 2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
20
Total36

Baseline characteristics

CharacteristicSham tDCS + Mindful Breathing TrainingTotalActive tDCS + Mindful Breathing Training
Age, Continuous20.5 years
STANDARD_DEVIATION 2.26
20.9 years
STANDARD_DEVIATION 2.19
21.2 years
STANDARD_DEVIATION 2.42
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants7 Participants4 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
16 Participants27 Participants11 Participants
Sex: Female, Male
Female
20 Participants36 Participants16 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 22
other
Total, other adverse events
21 / 2122 / 22
serious
Total, serious adverse events
0 / 210 / 22

Outcome results

Primary

Change in DLPFC Connectivity: Amygdala

Change in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: Right Amygdala and left DLPFC. Lower connectivity may represent a reduced tendency to engage in maladaptive, repetitive negative thinking. For r-values, 0 represents that the timeseries of the respective ROIs are not correlated. A better outcome may be indexed by lower connectivity (e.g., negative R values), which may represent a greater ability of the DLPFC to downregulate the amygdala and, which in turn may reduce the tendency to engage in maladaptive, repetitive negative thinking.

Time frame: Baseline and 5 week

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in DLPFC Connectivity: Amygdala0.0977 r-valueStandard Deviation 0.123
Sham tDCS + Mindful Breathing TrainingChange in DLPFC Connectivity: Amygdala-0.057 r-valueStandard Deviation 0.133
Primary

Change in DLPFC Connectivity: DMN

Change in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: default mode network and left DLPFC. Lower DLPFC and DMN connectivity may represent adaptive switching between thinking states to focus on a task at hand or to engage in more reflective, introspective thinking patterns. For r-values, 0 represents that the timeseries of the respective ROIs are not correlated. Change in dorsolateral prefrontal cortex connectivity with the salience network and the default mode using functional MRI compared between treatment groups: default mode network and left DLPFC. A better outcome may be indexed by lower DLPFC and DMN connectivity (e.g., negative R values), which may represent adaptive switching between thinking states to focus on a task at hand or to engage in more reflective, introspective thinking patterns.

Time frame: 5 weeks from baseline

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in DLPFC Connectivity: DMN0.0582 r-valueStandard Deviation 0.139
Sham tDCS + Mindful Breathing TrainingChange in DLPFC Connectivity: DMN-0.00604 r-valueStandard Deviation 0.106
Secondary

Change in Depression MADRS-S

Montgomery-Åsberg Depression Rating Scale - self-assessment (MADRS-S) measures change in severity of depression symptoms over time. Treatment response will be measured using the MADRS-S and a \ 50% reduction in depression severity, i.e. total MADRS-S score, will indicate a positive response to treatment. The scale includes 9 items that are rated by participants on a 4-point Likert scale ranging from 0 - 3. Half-point scores are also possible, i.e 0.5, 1.5, 2.5. Participants rate their symptoms from over the past 3 days and the range of total possible scores is 0 - 27, with a higher score indicating greater severity of symptoms. Bondolfi et al. (2010) found good internal consistency for the MADRS-S, as well as good concurrent validity between the MADRS (clinician administered) and the MADRS-S. Lastly, the MADRS-S was found to be sensitive to change in depression symptoms over time.

Time frame: Baseline and 5 weeks

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in Depression MADRS-S6.47 units on a scaleStandard Deviation 4.69
Sham tDCS + Mindful Breathing TrainingChange in Depression MADRS-S5.95 units on a scaleStandard Deviation 4.04
Secondary

Change in Mindfulness FMI

Freiburg Mindfulness Inventory (FMI) assesses curious attitude toward the mindfulness experience. The FMI contains 14 statements related to mindfulness experiences. Participants are requested to rate each statement according to a 4-point Likert scale ranging from Rarely to Almost Always. An increase in the FMI total score would indicate an increase in mindfulness. Walach et al. (2006) reported that the FMI is a valid and reliable measure of mindfulness. Total scores range from 14 to 56.

Time frame: Baseline and 9 weeks

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in Mindfulness FMI9.07 number on a scaleStandard Deviation 8.3
Sham tDCS + Mindful Breathing TrainingChange in Mindfulness FMI6.72 number on a scaleStandard Deviation 7.4
Secondary

Change in Mindfulness MAAS

Mindful Attention and Awareness Scale (MAAS) measures presence or absence of awareness of what is happening in the present. The MAAS consists of 15 items. Participants are requested to rate each item according to a 6-point Likert scale with the following options: Almost Always, Very Frequently, Somewhat Frequently, Somewhat Infrequently, Very Infrequently, and Almost Never. Previous study reported that the MAAS was internally consistent and a reliable measure. MAAS score ranges from 1 to 6, with a higher score indicating a greater awareness of inner experiences and mindfulness. In the present study, an increase in the total MAAS score would indicate an increase in presence of awareness of what is happening in the present.

Time frame: Baseline and 9 weeks

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in Mindfulness MAAS0.929 units on a scaleStandard Deviation 0.992
Sham tDCS + Mindful Breathing TrainingChange in Mindfulness MAAS0.352 units on a scaleStandard Deviation 0.859
Secondary

Change in Rumination RRS

Ruminative Response Scale (RRS) measures rumination, which refers to thoughts and behaviors centered around one's symptoms and their causes, as well as potential consequences. Nolen-Hoeksema, Morrow, & Fredrickson (1993) reported that ruminative thoughts correlated with depressed mood. They further reported a consistency in ruminative responses over a 30-day period. The RRS will be used to measure changes in rumination in the present study. The measure consists of a total of 22 statements that describe ruminative thoughts and participants are requested to rate each statement on a scale of 1 - 4, 1 being Almost Never and 4 being Almost Always. Change in rumination corresponds with a change in the total RRS score. Total scores range from 22 to 88.

Time frame: Baseline and 9 weeks

ArmMeasureValue (MEAN)Dispersion
Active tDCS + Mindful Breathing TrainingChange in Rumination RRS13.9 units on a scaleStandard Deviation 16.6
Sham tDCS + Mindful Breathing TrainingChange in Rumination RRS16.1 units on a scaleStandard Deviation 12.7
Secondary

Safety: Serious and Non-Serious Adverse Events

Measure of occurrence of negative side-effects from treatment. Side effects will be collected via participant self-report. Number of serious and non-serious adverse events will be considered in determining safety of the treatment. A higher number of adverse events will indicate lower treatment safety.

Time frame: 9 weeks

ArmMeasureValue (NUMBER)
Active tDCS + Mindful Breathing TrainingSafety: Serious and Non-Serious Adverse Events486 adverse events
Sham tDCS + Mindful Breathing TrainingSafety: Serious and Non-Serious Adverse Events654 adverse events
Secondary

Tolerability: Drop-Out

Number of participants who drop-out due to inability to tolerate treatment. A high number of participant drop-outs will indicate a lower level of tolerability of the treatment.

Time frame: 9 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Active tDCS + Mindful Breathing TrainingTolerability: Drop-Out0 Participants
Sham tDCS + Mindful Breathing TrainingTolerability: Drop-Out1 Participants
Secondary

Tolerability: Enrollment and Drop-Out

Number of participants enrolled. A high number of participants enrolled will indicate a higher level of tolerability of the treatment.

Time frame: 9 weeks

ArmMeasureValue (NUMBER)
Active tDCS + Mindful Breathing TrainingTolerability: Enrollment and Drop-Out21 participants
Sham tDCS + Mindful Breathing TrainingTolerability: Enrollment and Drop-Out22 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026